[{"id":"3459cfe0-8df3-41ce-b99a-ba11d3ea3232","acronym":"EVEREST-2","url":"https://clinicaltrials.gov/study/NCT06051695","created_at":"2023-09-25T14:10:18.366Z","updated_at":"2024-07-02T16:34:59.359Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","source_id_and_acronym":"NCT06051695 - EVEREST-2","lead_sponsor":"A2 Biotherapeutics Inc.","biomarkers":" HLA-A • MSLN","pipe":" | ","alterations":" MSLN expression • HLA-A*02","tags":["HLA-A • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • HLA-A*02"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 04/03/2024","start_date":" 04/03/2024","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2024-06-04"},{"id":"67a7cc8f-4495-4593-a5ec-9a4e0b7286d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02414269","created_at":"2021-01-18T11:32:05.371Z","updated_at":"2024-07-02T16:35:02.997Z","phase":"Phase 1/2","brief_title":"Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin","source_id_and_acronym":"NCT02414269","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PD-L1 • MSLN","pipe":" | ","alterations":" MSLN expression","tags":["PD-L1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • cyclophosphamide intravenous • iCasp9M28z T cell infusion"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-05-17"},{"id":"09261b2f-42ac-4b72-856f-4daf46603021","acronym":"NCI10208","url":"https://clinicaltrials.gov/study/NCT03816358","created_at":"2021-01-18T18:51:22.211Z","updated_at":"2024-07-02T16:35:03.288Z","phase":"Phase 1","brief_title":"Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer","source_id_and_acronym":"NCT03816358 - NCI10208","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • gemcitabine • anetumab ravtansine (BAY 94-9343) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 12/09/2019","start_date":" 12/09/2019","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-05-16"},{"id":"1feb857d-51e5-4682-a570-aafec2b08650","acronym":"","url":"https://clinicaltrials.gov/study/NCT05568680","created_at":"2022-10-06T14:56:16.043Z","updated_at":"2024-07-02T16:35:03.301Z","phase":"Phase 1","brief_title":"SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma","source_id_and_acronym":"NCT05568680","lead_sponsor":"Verismo Therapeutics","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SynKIR-110"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/30/2023","start_date":" 03/30/2023","primary_txt":" Primary completion: 03/15/2026","primary_completion_date":" 03/15/2026","study_txt":" Completion: 03/30/2026","study_completion_date":" 03/30/2026","last_update_posted":"2024-05-16"},{"id":"cadff643-56b0-4e97-baf3-eaa0cd1d40bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT05693844","created_at":"2023-01-23T16:00:11.670Z","updated_at":"2024-07-02T16:35:04.514Z","phase":"Phase 1/2","brief_title":"Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT05693844","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • CD40 ligand expressing MSLN-CAR T"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/20/2023","start_date":" 01/20/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-10"},{"id":"430c3067-053f-432e-8dd9-54e297aab048","acronym":"","url":"https://clinicaltrials.gov/study/NCT04577326","created_at":"2021-01-29T07:21:30.020Z","updated_at":"2024-07-02T16:35:06.711Z","phase":"Phase 1","brief_title":"Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma","source_id_and_acronym":"NCT04577326","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • ATA2271 • cyclophosphamide intravenous • engineered autologous T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/30/2020","start_date":" 09/30/2020","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-05-01"},{"id":"237b354a-5aa6-4026-9efe-63dba3502553","acronym":"","url":"https://clinicaltrials.gov/study/NCT05451849","created_at":"2022-07-11T11:54:54.962Z","updated_at":"2024-07-02T16:35:16.022Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer","source_id_and_acronym":"NCT05451849","lead_sponsor":"TCR2 Therapeutics","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TC-510"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 06/21/2022","start_date":" 06/21/2022","primary_txt":" Primary completion: 10/30/2028","primary_completion_date":" 10/30/2028","study_txt":" Completion: 10/30/2028","study_completion_date":" 10/30/2028","last_update_posted":"2024-03-06"},{"id":"f8516452-54df-4277-8f56-8aa72d1fb00e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03907852","created_at":"2021-01-18T19:14:14.258Z","updated_at":"2025-02-25T14:28:16.858Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer","source_id_and_acronym":"NCT03907852","lead_sponsor":"TCR2 Therapeutics","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • gavocabtagene autoleucel (TC-210) • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/15/2019","start_date":" 04/15/2019","primary_txt":" Primary completion: 11/02/2028","primary_completion_date":" 11/02/2028","study_txt":" Completion: 11/02/2028","study_completion_date":" 11/02/2028","last_update_posted":"2024-03-06"},{"id":"77e12794-7dd2-4ce2-bacc-b40dca21f7bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05375825","created_at":"2022-05-17T12:54:06.483Z","updated_at":"2024-07-02T16:35:21.326Z","phase":"Phase 1","brief_title":"Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin","source_id_and_acronym":"NCT05375825","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LMB-100"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 02/06/2024","start_date":" 02/06/2024","primary_txt":" Primary completion: 12/18/2024","primary_completion_date":" 12/18/2024","study_txt":" Completion: 12/18/2024","study_completion_date":" 12/18/2024","last_update_posted":"2024-02-01"},{"id":"22ffb21f-989e-4653-87ef-38c78fadff5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03054298","created_at":"2021-01-18T15:02:34.204Z","updated_at":"2024-07-02T16:35:22.364Z","phase":"Phase 1","brief_title":"CAR T Cells in Mesothelin Expressing Cancers","source_id_and_acronym":"NCT03054298","lead_sponsor":"University of Pennsylvania","biomarkers":" PD-L1","pipe":" | ","alterations":" MSLN expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TmMSTN-01"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 04/06/2017","start_date":" 04/06/2017","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-01-24"},{"id":"3e892831-b0ba-4503-947a-efcabbf14146","acronym":"","url":"https://clinicaltrials.gov/study/NCT05623488","created_at":"2022-11-21T14:57:07.845Z","updated_at":"2024-07-02T16:35:22.341Z","phase":"Phase 1","brief_title":"CAR T Cells in Mesothelin-Expressing Breast Cancer","source_id_and_acronym":"NCT05623488","lead_sponsor":"University of Pennsylvania","biomarkers":" HER-2 • ER • PGR • MSLN","pipe":" | ","alterations":" ER positive • HER-2 negative • ER negative • MSLN expression • PGR positive • PGR negative","tags":["HER-2 • ER • PGR • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER negative • MSLN expression • PGR positive • PGR negative"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 02/06/2023","start_date":" 02/06/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2038","study_completion_date":" 02/01/2038","last_update_posted":"2024-01-24"},{"id":"1709c9a1-ac1e-4f56-aabe-efd83c0933f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03126630","created_at":"2021-01-18T15:24:22.600Z","updated_at":"2024-07-02T16:35:23.903Z","phase":"Phase 1/2","brief_title":"Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma","source_id_and_acronym":"NCT03126630","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • MSLN","pipe":" | ","alterations":" PD-L1 expression • MSLN expression","tags":["PD-L1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • anetumab ravtansine (BAY 94-9343) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 10/04/2018","start_date":" 10/04/2018","primary_txt":" Primary completion: 07/08/2023","primary_completion_date":" 07/08/2023","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2024-01-10"},{"id":"bf40d4c1-dcd3-4943-b816-d258ac3bd571","acronym":"","url":"https://clinicaltrials.gov/study/NCT05508334","created_at":"2022-08-19T17:10:11.271Z","updated_at":"2024-07-02T16:35:23.981Z","phase":"Phase 1","brief_title":"A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT05508334","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e misitatug blivedotin (RC88)"],"overall_status":"Recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 01/30/2023","start_date":" 01/30/2023","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-01-10"},{"id":"6c76a251-4026-4ad4-94d6-b2b81e644662","acronym":"","url":"https://clinicaltrials.gov/study/NCT04809766","created_at":"2021-03-22T11:52:20.228Z","updated_at":"2024-07-02T16:35:24.105Z","phase":"Phase 1","brief_title":"Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT04809766","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-A • MSLN","pipe":" | ","alterations":" MSLN expression • HLA-A*02","tags":["HLA-A • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV • FH-TCR-Tᴍsʟɴ • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 12/14/2021","start_date":" 12/14/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-01-09"},{"id":"3be9f507-67a2-4cb7-a07b-b039d2c87116","acronym":"","url":"https://clinicaltrials.gov/study/NCT05164666","created_at":"2021-12-21T16:53:48.131Z","updated_at":"2024-07-02T16:35:25.177Z","phase":"Phase 1","brief_title":"A Study of TAK-103 in Adult With Solid Tumors","source_id_and_acronym":"NCT05164666","lead_sponsor":"Takeda","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NIB103"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2","initiation":"Initiation: 01/05/2022","start_date":" 01/05/2022","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2023-12-27"},{"id":"99889667-7df9-4ba0-9746-9b7586ccaa67","acronym":"","url":"https://clinicaltrials.gov/study/NCT05779917","created_at":"2023-03-22T14:03:05.395Z","updated_at":"2024-07-02T16:35:29.095Z","phase":"Phase 1","brief_title":"Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers","source_id_and_acronym":"NCT05779917","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mesothelin/GPC3/GUCY2C-CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/10/2023","start_date":" 03/10/2023","primary_txt":" Primary completion: 03/10/2026","primary_completion_date":" 03/10/2026","study_txt":" Completion: 03/10/2033","study_completion_date":" 03/10/2033","last_update_posted":"2023-11-15"},{"id":"ca161a5b-e2be-463d-91d5-d7590fad91e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01393483","created_at":"2021-01-18T05:43:20.137Z","updated_at":"2024-07-02T16:35:34.994Z","phase":"","brief_title":"Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)","source_id_and_acronym":"NCT01393483","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 371","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-10-03"},{"id":"5deea24a-3e42-4778-ab8c-7a751c529263","acronym":"","url":"https://clinicaltrials.gov/study/NCT04727554","created_at":"2021-01-29T07:21:48.844Z","updated_at":"2024-07-02T16:35:36.003Z","phase":"Phase 1","brief_title":"Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT04727554","lead_sponsor":"Amgen","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e inezetamab (AMG994) • zeluvalimab (AMG 404)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 04/29/2021","start_date":" 04/29/2021","primary_txt":" Primary completion: 06/05/2023","primary_completion_date":" 06/05/2023","study_txt":" Completion: 06/05/2023","study_completion_date":" 06/05/2023","last_update_posted":"2023-09-22"},{"id":"f384c94c-4626-4812-85bd-523c626b0875","acronym":"","url":"https://clinicaltrials.gov/study/NCT04034238","created_at":"2021-01-18T19:47:53.888Z","updated_at":"2024-07-02T16:35:41.280Z","phase":"Phase 1","brief_title":"Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors","source_id_and_acronym":"NCT04034238","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tofacitinib • LMB-100"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 08/29/2019","start_date":" 08/29/2019","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 11/19/2021","study_completion_date":" 11/19/2021","last_update_posted":"2023-08-01"},{"id":"faadd5d4-3c80-4487-b26e-e3f81311dd1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02792114","created_at":"2021-01-18T13:42:21.295Z","updated_at":"2024-07-02T16:35:44.191Z","phase":"Phase 1","brief_title":"T-Cell Therapy for Advanced Breast Cancer","source_id_and_acronym":"NCT02792114","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • PD-L1 • MSLN","pipe":" | ","alterations":" HER-2 negative • MSLN expression","tags":["HER-2 • PD-L1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • cyclophosphamide intravenous • rimiducid (AP1903)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 186","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-06-30"},{"id":"9fff9757-a7af-45a1-92b1-4c86a11926c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05403554","created_at":"2022-06-03T12:55:16.390Z","updated_at":"2024-07-02T16:35:47.006Z","phase":"Phase 1","brief_title":"A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers","source_id_and_acronym":"NCT05403554","lead_sponsor":"Light Chain Bioscience - Novimmune SA","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NI-1801"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 04/29/2022","start_date":" 04/29/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2023-05-29"},{"id":"8c0aa7e0-1334-4262-9265-0f911e6ba67b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05856643","created_at":"2023-05-12T17:04:51.685Z","updated_at":"2024-07-02T16:35:48.170Z","phase":"Phase 1","brief_title":"Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Ovarian Epithelial Carcinoma","source_id_and_acronym":"NCT05856643","lead_sponsor":"Shantou University Medical College","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SZ011"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2023-05-12"},{"id":"0e2c53e2-5daa-4613-9cf4-4a3a1038b338","acronym":"","url":"https://clinicaltrials.gov/study/NCT03198052","created_at":"2021-01-18T15:46:10.109Z","updated_at":"2024-07-02T16:35:55.664Z","phase":"Phase 1","brief_title":"GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers","source_id_and_acronym":"NCT03198052","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA","pipe":" | ","alterations":" MSLN expression • EGFR positive • GPC3 expression","tags":["EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • EGFR positive • GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2023-02-14"},{"id":"afcec8a4-0dae-4657-8947-be495c4de8d2","acronym":"ARCS-Multi","url":"https://clinicaltrials.gov/study/NCT03102320","created_at":"2021-01-18T15:17:05.990Z","updated_at":"2025-02-25T15:53:43.857Z","phase":"Phase 1b","brief_title":"Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors","source_id_and_acronym":"NCT03102320 - ARCS-Multi","lead_sponsor":"Bayer","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • anetumab ravtansine (BAY 94-9343)"],"overall_status":"Completed","enrollment":" Enrollment 173","initiation":"Initiation: 05/26/2017","start_date":" 05/26/2017","primary_txt":" Primary completion: 09/16/2020","primary_completion_date":" 09/16/2020","study_txt":" Completion: 07/26/2021","study_completion_date":" 07/26/2021","last_update_posted":"2022-06-30"}]